| Name | Title | Contact Details |
|---|
We are a genome editing company developing genetic medicines for the fight against rare pediatric diseases. GeneRide™ is a promoterless and nuclease-free approach to gene insertion which may improve the safety profile of AAV based gene therapies With GeneRide™, the therapeutic gene is site-specifically integrated into the genome allowing durable gene expression in dividing cells and mature tissues. Furthermore, therapeutic gene expression is regulated by the targeted locus so production can be limited to specific cell types.
Sierra Oncology is a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Our lead drug candidate, momelotinib, is a potent, selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing a range of meaningful anemia benefits, including eliminating or reducing the need for frequent blood transfusions, as well as achieving substantive spleen and constitutional symptom control. We are also advancing SRA737 and SRA141. SRA737, is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1). We are pursuing an innovative development plan for SRA737, which is currently being evaluated in two Phase 1/2 clinical trials in patients with advanced cancer. SRA737-01 is intended to evaluate SRA737`s potential to induce synthetic lethality as monotherapy, while SRA737-02 is intended to evaluate the combination of SRA737 potentiated by subtherapeutic, low dose gemcitabine. Concurrently, we are conducting preclinical research evaluating SRA737 in combination with other DDR-targeted agents, including PARP inhibitors, as well as with immuno-oncology therapeutics, that may guide a potential next wave of clinical development for our asset, possibly further broadening its therapeutic utility. SRA141, a potent, selective, orally bioavailable small molecule inhibitor of cell division cycle 7 kinase (Cdc7). Cdc7 is a key regulator of DNA replication and is involved in the DDR network, making it a compelling emerging target for potential treatment across a broad range of tumor types. An Investigational New Drug Application (IND) submission to the U.S. Food and Drug Administration (FDA) is being prepared in order to commence clinical trials with this drug candidate.
Cytek Biosciences Inc. is a leading manufacturer and supplier of flow cytometry products and services. Cytek`s compact, affordable instruments and wide ranging support offerings are used by researchers and clinicians all over the world. Flow cytometry is a powerful analytical tool used for identifying and quantifying cellular characteristics on a cell-by-cell basis up to tens of thousands of cells per second. This technology is used in research and clinical studies with various biomedical and therapeutic applications such as investigating the role of the body`s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients. Flow cytometry has many advantages over traditional microscopy since it enables the analysis of a greater number of cells in a fraction of the time. At Cytek, we are focused on accelerating the adoption of flow cytometry for one simple reason: to fuel scientific discovery. We have leveraged our highly experienced, best-in-the-business team to bring forth an innovative new class of flow cytometry solutions. These solutions deliver deep biological insights at an affordable price, provide high-end capabilities, and bring simplified workflows to more researchers than ever before. As a company, we also seek to maintain high ethical standards and a culture that values honesty, integrity and transparency in all that we do. Company decisions are driven by what is right for scientific discovery and customer support. We are committed to our employees, to the environment in which we live and to the communities we serve worldwide. Cytek is headquartered in Fremont, California with branch offices and distribution channels across the globe.
The world’s most innovative and effective clean air technology against harmful ultra fine particles incl. COVID-19. Developed in Germany, assembled in the US.
Jasper Clinical Research and Development, Inc. is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.